Skip to main content
Insights
/ Webinars

Accelerating Innovation with J&J

Accelerating Innovation with J&J

Access webinar replay

Business email
First name
Last name
Company name
Job title
Which sector best reflects your role?
By submitting this form, you agree to receive email communications from Inpart as well as the storing and processing of your personal data by Inpart as detailed in the Privacy Statement. You may unsubscribe from these communications at any time.
Every year Inpart surveys biotechs worldwide on their partnering experiences, their partnering challenges, and their interactions with the world’s largest pharma companies. In our 2023 Partnering 2030 survey, Johnson & Johnson was ranked first amongst top pharma companies for its overall partnering experience.

Panelists

Ajay Gautam
Ajay Gautam
Vice President, Early Innovation Partnering, Johnson & Johnson Innovation, Asia Pacific

Collaborations with biotechs are a key contributor to J&J’s innovation strategy

J&J is one of the largest healthcare companies, operating across the spectrum of healthcare. It is exclusively focused on healthcare innovation to tackle the toughest health challenges, through its two business sectors, J&J Innovative Medicine and J&J MedTech.

Watch the replay to learn:​

  • What makes partnering with J&J different
  • What innovations J&J is focused on in 2024
  • How to position your biotech for success at the BIO International Convention

Learn more about Inpart Campaigns

Our bespoke R&D scouting solution allows companies to leverage a global network of academics and biotechs to source new solutions to their requirements and technical challenges.

Request a demo